Concord Drugs Limited (BOM:538965)
India
· Delayed Price · Currency is INR 76.91
+2.71 (3.65%)
At close: Mar 10, 2026
Concord Drugs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 512.41 | 452.45 | 449.25 | 520.81 | 589.57 | 513.57 | Upgrade
|
| Other Revenue | 0 | 0 | - | - | 0.86 | 0.87 | Upgrade
|
| Revenue | 512.41 | 452.45 | 449.25 | 520.81 | 590.43 | 514.44 | Upgrade
|
| Revenue Growth (YoY) | 1.48% | 0.71% | -13.74% | -11.79% | 14.77% | 0.03% | Upgrade
|
| Cost of Revenue | 418.51 | 356.47 | 337.33 | 415.96 | 425.7 | 434.11 | Upgrade
|
| Gross Profit | 93.9 | 95.98 | 111.92 | 104.85 | 164.73 | 80.33 | Upgrade
|
| Selling, General & Admin | 44.56 | 46.35 | 60.76 | 49.19 | 48.91 | 37.55 | Upgrade
|
| Other Operating Expenses | 8.58 | 8.29 | 10.73 | 9.94 | 7.55 | 9.71 | Upgrade
|
| Operating Expenses | 67.06 | 68.94 | 87.04 | 75.38 | 125.59 | 60.92 | Upgrade
|
| Operating Income | 26.84 | 27.04 | 24.87 | 29.46 | 39.14 | 19.41 | Upgrade
|
| Interest Expense | -18.21 | -19.19 | -18.17 | -16.34 | -15.79 | -13.31 | Upgrade
|
| Interest & Investment Income | 0.14 | 0.14 | 0.09 | 0.06 | 0.12 | 0.08 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.94 | -1.08 | -0.5 | -0.7 | -0.99 | -0.89 | Upgrade
|
| EBT Excluding Unusual Items | 7.84 | 6.91 | 6.29 | 12.49 | 22.48 | 5.29 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | 37.63 | Upgrade
|
| Pretax Income | 7.84 | 6.91 | 6.29 | 12.49 | 22.48 | 42.92 | Upgrade
|
| Income Tax Expense | 2.18 | 3.55 | 1.57 | 2.63 | 6.54 | 10.1 | Upgrade
|
| Net Income | 5.66 | 3.36 | 4.72 | 9.86 | 15.94 | 32.82 | Upgrade
|
| Net Income to Common | 5.66 | 3.36 | 4.72 | 9.86 | 15.94 | 32.82 | Upgrade
|
| Net Income Growth | - | -28.82% | -52.08% | -38.19% | -51.42% | 899.60% | Upgrade
|
| Shares Outstanding (Basic) | 12 | 10 | 10 | 9 | 9 | 9 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 10 | 10 | 9 | 9 | 9 | Upgrade
|
| Shares Change (YoY) | 25.47% | - | 7.35% | 6.53% | - | - | Upgrade
|
| EPS (Basic) | 0.45 | 0.34 | 0.47 | 1.06 | 1.82 | 3.75 | Upgrade
|
| EPS (Diluted) | 0.45 | 0.34 | 0.47 | 1.06 | 1.82 | 3.75 | Upgrade
|
| EPS Growth | - | -28.47% | -55.57% | -41.87% | -51.47% | 898.78% | Upgrade
|
| Free Cash Flow | - | 13.89 | -2.26 | 8.06 | -16.82 | -36.74 | Upgrade
|
| Free Cash Flow Per Share | - | 1.39 | -0.23 | 0.87 | -1.92 | -4.20 | Upgrade
|
| Gross Margin | 18.32% | 21.21% | 24.91% | 20.13% | 27.90% | 15.62% | Upgrade
|
| Operating Margin | 5.24% | 5.98% | 5.54% | 5.66% | 6.63% | 3.77% | Upgrade
|
| Profit Margin | 1.10% | 0.74% | 1.05% | 1.89% | 2.70% | 6.38% | Upgrade
|
| Free Cash Flow Margin | - | 3.07% | -0.50% | 1.55% | -2.85% | -7.14% | Upgrade
|
| EBITDA | 40.21 | 41.34 | 40.43 | 45.72 | 56.79 | 33.06 | Upgrade
|
| EBITDA Margin | 7.85% | 9.14% | 9.00% | 8.78% | 9.62% | 6.43% | Upgrade
|
| D&A For EBITDA | 13.37 | 14.31 | 15.55 | 16.26 | 17.65 | 13.65 | Upgrade
|
| EBIT | 26.84 | 27.04 | 24.87 | 29.46 | 39.14 | 19.41 | Upgrade
|
| EBIT Margin | 5.24% | 5.98% | 5.54% | 5.66% | 6.63% | 3.77% | Upgrade
|
| Effective Tax Rate | 27.79% | 51.37% | 24.89% | 21.09% | 29.08% | 23.54% | Upgrade
|
| Revenue as Reported | 512.69 | 452.59 | 449.34 | 520.89 | 590.57 | 514.52 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.